Although anti-HER2 targeted therapy prolongs the survival of BC patients, and improves the control rate of extracranial lesions, the existence of the blood-brain barrier greatly weakens the killing effect of most systemic drugs on brain tumors. This evidence concerns the gene ERBB2 and breast cancer.